Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1 - Infected patients receiving abacavir in combination with HIV-1 protease inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 5, 2003, Pages 557-563

  Wu, Hulin ^a,b   Mellors, John ^c   Ruan, Ping ^b   McMahon, Deborah ^c   Kelleher, Dennis ^d   Lederman, Michael M ^e  

^a FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Evaluation of antiretroviral potency; Highly active antiretroviral therapy; Viral dynamics

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIROLOGY;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0042126735     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308150-00002     Document Type: Article

References (22)

1. Perelson AS, Nelson PW. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 1999;41:3-44.
2. Ding AA, Wu H. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Math Biosci. 1999;160:63-82.
3. Notermans DW, Goudsmit J, Danner SA, et al. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS. 1998;12:1483-1490.
4. Wu H, Lathey J, Spector S, et al. Viral dynamics and their relationship to baseline factors and week 24 virological response in non-perinatally HIV-1 infected adolescents receiving HAART [abstract 574]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003.
5. Mueller BU, Zeichner SL, Kuznetsov VA, et al. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. AIDS. 1998;12(Suppl):F191-F196.
6. Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in Human Immunodeficiency Virus Type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration and virological endpoints. J Infect Dis. 1999;179:799-807.
7. Wu H, Wu L. Identification of significant host factors for HIV dynamics modeled by nonlinear mixed-effect models. Stat Med. 2002;21:753-771.
8. Mittler J, Essunger P, Yuen GJ, et al. Short-term measures of relative efficacy predict longer-term reductions in Human Immunodeficiency Virus Type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother. 2001;45:1438-1443.
9. Huang W, De Gruttola V, Fischl M, et al. Pattern of plasma Human Immunodeficiency Virus Type 1 RNA response to antiretroviral therapy. J Infect Dis. 2001;183:1455-1465.
10. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet. 2001;358:1760-1765.
11. Wu H, Ding AA. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics. 1999;55:410-418.
12. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-191.
13. Wu H, Ding A, DeGruttola V. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? AIDS. 1999;13:429-430.
14. Ding AA, Wu H. A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies. Biometrics. 2000;56:16-23.
15. Ding AA, Wu H. Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. Biostatistics. 2001;2:13-29.
16. McMahon D, Lederman M, Haas DW, et al. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. Antiviral Ther. 2001;6:105-114.
17. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000;14:2635-2642.
18. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
19. Wu H, Ruan P, Ding AA, et al. Inappropriate model-fitting methods may lead to significant underestimates of viral decay rates in HIV dynamic studies. J Acquir Immune Defic Syndr. 1999;21:426-428.
20. Nowak MA, May RM. Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford: Oxford University Press; 2000.
21. Patki AH, Zielske SP, Sieg SF, et al. Preferential S phase entry and apoptosis of CD4+ T lymphocytes of HIV-1 infected patients after in vitro cultivation. Clin Immunol. 2000;97:241-247.
22. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002;109:681-688.